NCT05830669 Remote Ischemic Preconditioning in Septic Patients
| NCT ID | NCT05830669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universität Münster |
| Condition | Critically Ill |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2023-05-11 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2023-05-11 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury is a well-recognized complication in critically ill patients. Up to date there is no clinically established method to reduce the incidence or the severity of acute kidney injury. Remote ischemic preconditioning (RIPC) will be induced by three cycles of upper limb ischemia. The aim of the study is to reduce the incidence of AKI by implementing remote ischemic preconditioning (identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7(IGFBP7)
Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with sepsis \< 12 hours * Invasive ventilation for at least 24 hours (propofol-free-sedation) and/or vasopressor therapy * Unrestricted intensive care for at least 72 hours * Written informed consent Exclusion Criteria: * Pre-existing AKI * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Chronic dialysis dependency * Kidney transplant in the last 12 months * Oral antidiabetics, sulfonamides or nicorandil * Pregnancy or breastfeeding * Do-not-reanimate order * Participation in another interventional trial involving kidney outcomes within the last 3 months * Dependency on the investigator or center
Contact & Investigator
Melanie Meersch-Dini, MD
PRINCIPAL INVESTIGATOR
University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine
Frequently Asked Questions
Who can join the NCT05830669 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critically Ill. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05830669 currently recruiting?
Yes, NCT05830669 is actively recruiting participants. Contact the research team at meersch@uni-muenster.de for enrollment information.
Where is the NCT05830669 trial being conducted?
This trial is being conducted at Münster, Germany.
Who is sponsoring the NCT05830669 clinical trial?
NCT05830669 is sponsored by Universität Münster. The principal investigator is Melanie Meersch-Dini, MD at University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine. The trial plans to enroll 64 participants.